Notable insider buying and selling activity across public companies.
Tracking and analysis of reported insider transactions, including executive and director buying or selling. Insider activity can offer insight into internal confidence, valuation perceptions, and potential inflection points.
9,878 total articles
David Soergel, the Chief Medical Officer at Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), recently sold a block of company shares. This transaction occurred despite recent positive developments for the firm, including robust quarterly earnings and significant clinical data presentations regarding its drug candidate, Rezdiffra.The sale involved 1,0…
Jeffrey Dell, Chief Information Officer at Red Violet, Inc., executed a series of sales totaling 10,000 shares of the company's common stock on June 1, 2026. These transactions generated an approximate value of $574,350. The sale occurred while the underlying stock has experienced significant upward momentum and some analysis suggests it may be tra…
Scott H. Keeney, the President and Chief Executive Officer of nLIGHT, Inc., recently executed significant stock sales and made a charitable donation of shares. These personal transactions occurred against a backdrop of strong financial reporting for the first quarter of 2026, where the company surpassed analyst expectations and saw major increases …
Derek Dubner, the Chief Executive Officer and Chairman of the Board at Red Violet, Inc. (NASDAQ:RDVT), recently executed a sale of company shares totaling $689,160. This transaction occurred on June 1, 2026, involving 12,000 common stock shares. The sale takes place against a backdrop where the stock has appreciated by 17% over the past week and is…
The Chief Financial Officer of Red Violet, Inc. (NASDAQ:RDVT), Daniel MacLachlan, reported selling common stock totaling $689,160 on June 1, 2026. This transaction occurred as the company's stock had risen significantly over the past week and is currently trading above its indicated Fair Value. Separately, Red Violet announced robust financial resu…
Alexander Azoy, Chief Accounting Officer at Arcus Biosciences, Inc., sold a portion of his holdings in the biotechnology firm. This transaction occurred while the company's stock has experienced significant gains and reported first quarter financials that fell short of market expectations. Analysts remain active, with one firm raising its price tar…
Alphabet director Frances Arnold sold 102 shares of Class C Capital Stock on May 29, 2026, for a total value of $38,862. This sale was executed through a Rule 10b5-1 trading plan adopted by Arnold on August 21, 2025. The transaction occurs against the backdrop of strong performance metrics and significant industry developments, including major loan…
Howard Horn, the Chief Financial Officer of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), executed a transaction involving the disposal of company stock valued at $110,601 on June 1, 2026. This activity occurred while the stock traded significantly below its recent high. Meanwhile, the company reported first-quarter losses that missed analyst expec…
The recent sale of company stock by WEX Inc.'s Chief Operating Officer, Robert Joseph Deshaies, has occurred amidst a period of significant positive corporate developments. Mr. Deshaies sold 1,200 shares valued at $173,808 on May 28, 2026. This transaction takes place against a backdrop of WEX reporting strong first-quarter financial results and an…
Executive Vice President Andrew Callos sold a total value of $1.11 million in Cytokinetics common stock after utilizing exercised options. This transaction occurred against a backdrop of significant corporate activity for the company, including the German market entry of its heart drug Myqorzo and multiple large-scale capital offerings.
Cytokinetics' director, Edward M. Kaye, recently sold a substantial block of shares in the company's common stock. This transaction occurs against a backdrop of positive corporate developments for Cytokinetics Inc., including the launch of its heart drug Myqorzo in Germany, recent successful public offerings raising significant capital, and an elev…
Cytokinetics announced a significant commercial milestone with the market entry of its heart drug, Myqorzo, in Germany. These developments coincide with recent insider activity, including a director sale, and substantial financial fundraising efforts that underscore the company's current operational momentum and strategic planning.
A recent SEC Form 4 filing details the sale of company common stock by AAON director Gary D. Fields, totaling $2,663,800. The transaction occurs amid strong market performance for AAON, which reported better-than-expected first-quarter results and raised its full-year guidance. Analysts are also noting that the stock appears overvalued relative to …
Jonathan P. Faust, Executive Vice President and Chief Financial Officer at SANMINA CORP (NASDAQ:SANM), executed transactions totaling $2.67 million on May 29, 2026. This selling activity occurred against a backdrop of strong corporate performance, with Sanmina reporting an EPS of $3.16 and revenue reaching $4.01 billion for Q2 fiscal year 2026. The…
EnerSys's Chief Financial Officer, Andrea J. Funk, recently purchased a notable amount of the company's common stock. This insider activity occurs against a backdrop of positive corporate performance, including recent earnings that beat expectations and guidance suggesting continued momentum. However, analysis also points to valuation concerns, wit…
A collective disposal of approximately $1.16 billion worth of Medline Inc.'s (MDLN) Class A Common Stock occurred on May 28, 2026, through an underwritten public offering involving Hellman & Friedman affiliated funds. The transaction included the sale of 31,868,237 shares at a specific price point, followed by in-kind distributions to ultimate part…
Protagonist Therapeutics director William D. Waddill executed a sale of company common stock on May 29, 2026, using pre-arranged trading plans. This transaction occurred against a backdrop of significant analyst upgrades and positive projections for the firm's product platform, particularly Icotyde.
Ryan Harmer, Principal Accounting Officer at Cricut, Inc. (NASDAQ:CRCT), sold 17,267 shares of Class A Common Stock on May 28, 2026. The total value of the transaction was $71,210, with the average selling price calculated at $4.1241 per share. This activity occurs as CRCT shares trade near their 52-week low of $3.73 and have declined by 16% over t…
HealthEquity director Wellborn Gayle Furgurson recently sold a significant amount of common stock following the exercise of options. This activity occurred against a backdrop of strong corporate performance, as HealthEquity reported first-quarter fiscal year 2027 results that surpassed market expectations. Furthermore, analysts have updated their p…
Director Harvey Gutman recently sold a portion of his holdings in Metropolitan Bank Holding Corp. (MCB). This sale occurs against a backdrop of strong corporate performance, highlighted by Q1 2026 results that beat analyst expectations for both earnings per share and revenue. Furthermore, the bank is pursuing strategic expansion into the Western Un…
Raul Ramos, Senior Vice President of Latin American Operations at FirstCash Holdings (FCFS), sold a significant block of company stock. This insider transaction occurred against a backdrop of the firm announcing strong first-quarter financial results that surpassed market expectations. Following these positive earnings announcements, major investme…
Chief Operations Officer Frank Klein executed a pre-planned sale of Rocket Lab Corp (RKLB) common stock. This transaction occurs against a backdrop of major corporate developments, including securing an $816 million contract for the Space Development Agency's Tracking Layer Tranche 3 constellation and completing the acquisition of Motiv Space Syste…
Marvin Bradford Clevenger, President of Rocket Lab USA, Inc., sold a total value of $513,355 worth of company stock on May 28, 2026. This transaction occurs against a backdrop of positive corporate developments for Rocket Lab Corp (NASDAQ:RKLB), including the successful System Requirements Review for a major defense contract and the acquisition of …
Senior Vice President Arjun Kampani sold a substantial amount of Rocket Lab common stock through an automated trading plan. Concurrently, the company secured significant government contracts and completed key acquisitions, bolstering its standing in the defense and commercial space sectors. The broader space market is also reacting to major industr…
Alexander R. Slusky, a director at Rocket Lab Corp., recently sold 60,000 shares of common stock totaling $8.96 million. This transaction occurred as the company's stock traded near its 52-week high, amid positive operational news, including a System Requirements Review completion and an acquisition that enhances its space robotics capabilities.
